Clinical Trial Update: MT2022-01: MSCs for ALD [Phase 1]

View source ↗

Summary

The Phase 1 trial MT2022-01 evaluating mesenchymal stem cells for Cerebral Adrenoleukodystrophy is currently suspended. The update provides limited detail on th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Adrenoleukodystrophy

Drugs mentioned

• MT2022-01 (mesenchymal stem cells)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Cerebral Adrenoleukodystrophy | Phase 1 | Status: SUSPENDED